Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/130016
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Outcomes for Australian children with relapsed/refractory acute lymphoblastic leukaemia treated with blinatumomab |
Author: | Sutton, R. Pozza, L.D. Khaw, S.L. Fraser, C. Revesz, T. Chamberlain, J. Mitchell, R. Trahair, T.N. Bateman, C.M. Venn, N.C. Law, T. Ong, E. Heatley, S.L. McClure, B.J. Meyer, C. Marschalek, R. Henderson, M.J. Cross, S. White, D.L. Kotecha, R.S. |
Citation: | Pediatric Blood and Cancer, 2021; 68(5):1-7 |
Publisher: | Wiley |
Issue Date: | 2021 |
ISSN: | 0098-1532 1545-5017 |
Statement of Responsibility: | Rosemary Sutton, Luciano Dalla Pozza, Seong Lin Khaw, Chris Fraser, Tom Revesz, Janis Chamberlain, Richard Mitchell, Toby N. Trahair, Caroline M. Bateman, Nicola C. Venn, Tamara Law, Erika Ong, Susan L. Heatley, Barbara J. McClure, Claus Meyer, Rolf Marschalek, Michelle J. Henderson, Siobhan Cross, Deborah L. White, Rishi S. Kotecha |
Abstract: | We report on the Australian experience of blinatumomab for treatment of 24 children with relapsed/refractory precursor B‐cell acute lymphoblastic leukaemia (B‐ALL) and high‐risk genetics, resulting in a minimal residual disease (MRD) response rate of 58%, 2‐year progression‐free survival (PFS) of 39% and 2‐year overall survival of 63%. In total, 83% (n = 20/24) proceeded to haematopoietic stem cell transplant, directly after blinatumomab (n = 12) or following additional salvage therapy (n = 8). Four patients successfully received CD19‐directed chimeric antigen receptor T‐cell therapy despite prior blinatumomab exposure. Inferior 2‐year PFS was associated with MRD positivity (20%, n = 15) and in KMT2A‐rearranged infants (15%, n = 9). Our findings highlight that not all children with relapsed/refractory B‐ALL respond to blinatumomab and factors such as blast genotype may affect prognosis. |
Keywords: | Acute lymphoblastic leukaemia; blinatumomab; paediatric; refractory; relapse |
Rights: | © 2021Wiley Periodicals LLC |
DOI: | 10.1002/pbc.28922 |
Grant ID: | http://purl.org/au-research/grants/nhmrc/1142627 |
Published version: | http://dx.doi.org/10.1002/pbc.28922 |
Appears in Collections: | Aurora harvest 4 Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.